Back To TOP

Our Services Patient Assistance Programs

If you are worried about paying for ACTEMRA® (tocilizumab), we can help. We offer programs to help you access ACTEMRA, regardless of your ability to pay. Visit Find Patient Assistance to learn more.

 

Learn More About
ACTEMRA
  • LEARN about treatment with ACTEMRA
  • NOW AVAILABLE: ACTEMRA SC for
    self-injection
  • LEARN HOW the Genentech Rheumatology Co-pay Card program can help with your out-of-pocket costs for ACTEMRA. It provides up to $10,000 per 12-month period.
  • Form Patient Authorization and Notice of Release of Information

This information does not take the place of talking to your healthcare provider about either your medical condition or your treatment with ACTEMRA. Talk with your healthcare provider if you have any questions about your treatment with ACTEMRA.

INDICATION

ACTEMRA is a prescription medicine called an interleukin-6 (IL-6) receptor antagonist. ACTEMRA is used to treat:

  • Adults with moderately to severely active rheumatoid arthritis (RA) after at least one other medicine called a disease modifying antirheumatic drug (DMARD) has been used and did not work well
  • Patients with active polyarticular juvenile idiopathic arthritis (PJIA) or active systemic juvenile idiopathic arthritis (SJIA) 2 years of age and older

ACTEMRA is not approved for subcutaneous use in people with PJIA or SJIA.

 

IMPORTANT SIDE EFFECT INFORMATION

Some people have serious infections while taking ACTEMRA, including tuberculosis (TB) and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have died from these infections.

Other serious side effects of ACTEMRA include tears (perforation) of the stomach and intestines, changes in blood test results (including low neutrophil count, low platelet count, increase in certain liver function tests, and increase in blood cholesterol levels), hepatitis B infection becoming an active infection again, and nervous system problems.

ACTEMRA affects the immune system and may increase your risk of certain cancers.

Serious allergic reactions, including death, can happen with ACTEMRA. These reactions may happen with any infusion or injection of ACTEMRA, even if they did not occur with an earlier infusion or injection. Patients must tell their doctor if they have had a previous reaction to ACTEMRA. Patients should not take ACTEMRA if they are allergic to it or any of its ingredients.

Common side effects with ACTEMRA in patients with RA include upper respiratory tract infections (common cold, sinus infections), headache, and increased blood pressure (hypertension).

Common side effects with ACTEMRA in patients with PJIA or SJIA include upper respiratory tract infections (common cold, sinus infections), headache, and diarrhea.

Patients must tell their healthcare provider if they plan to become pregnant or are pregnant. It is not known if ACTEMRA will harm an unborn baby. Genentech has a registry for pregnant women who take ACTEMRA. Patients who are pregnant or become pregnant while taking ACTEMRA must contact the registry at 1-877-311-8972 and talk to their healthcare provider.

Patients must call their healthcare provider for medical advice about any side effects. You may report side effects to the FDA at
1-800-FDA-1088 or
www.FDA.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.

Please see accompanying full Prescribing Information, including Boxed Warning and Medication Guide, for additional Important Safety Information.

ACTEMRA® and its logo are trademarks of Chugai Seiyaku Kabushiki Kaisha Corp., a member of the Roche Group.

The Access Solutions logo is a registered trademark of Genentech, Inc.